Business, energy, technology, markets and global industry news from Business News Today

Skip to content

Home
Pharma & Biotech
Medical Devices & Diagnostics
Features & Analysis

Home
Pharma & Biotech
Medical Devices & Diagnostics
Features & Analysis

full capsids

PharmaDeviceNews full capsids

Representative image: Advanced AAV gene therapy manufacturing platforms such as AAVnerGene’s AAVone 2.1 are drawing attention as biotech developers look to improve vector productivity, full-capsid yield, and scalable production economics.

Pharma & Biotech

Why AAVnerGene’s AAVone 2.1 could matter for next-generation gene therapy manufacturing

by Pallavi Madhiraju
May 9, 2026
0 Comments

AAV gene therapy needs better economics. AAVnerGene’s AAVone 2.1 tests whether single-plasmid production can ease the scale-up squeeze.

Read More

Latest news and features

Innoviva’s antibiotics are growing 45%, so why did the company report a $73.9m loss?
Summit Therapeutics has $2bn from AstraZeneca and stronger cancer survival data, but will the FDA approve ivonescimab?
Evommune bets $30m on a VAV1 degrader that could challenge JAK inhibitors, but can it deliver safer autoimmune treatment?
Iadademstat shows 95% response rate in leukemia as Oryzon Genomics prepares Phase 3 development
FDA grants breakthrough designation to daridorexant following 50-minute sleep improvement in children
Pelareorep shows promising HPV-targeted immune activity as Oncolytics Biotech advances cancer research
Annamycin leukemia trial progresses toward pivotal dose selection after encouraging interim results
Kairos Pharma highlights 17.7-month progression-free survival with ENV-105 combination in metastatic prostate cancer
Bayer’s asundexian cut recurrent stroke risk by 26%, but can new AHA evidence strengthen its global approval prospects?
Imperative Care reports comparable 30-day outcomes for women and men in 106-patient pulmonary embolism analysis
EVX-01 personalized cancer vaccine moves into focus as Evaxion examines broader immune responses
PAS-004 advances toward Phase 2 as Pasithea seeks new treatment approach for cutaneous neurofibromas

POPULAR NEWS

plated Skin Science’s new BODY Serum brings platelet-derived exosome skincare beyond the face, targeting signs of aging, texture and hydration across the body. Representative image.

Pharma & Biotech

Rion Aesthetics expands plated Skin Science exosome platform with $338 BODY Serum

August 19, 2026

Pharma & Biotech

Omabit raises $2m to connect fragmented clinical evidence, but can AI improve drug development decisions?

October 27, 2026

Medical Devices & Diagnostics

Presage Technologies SmartSpectra cleared for contactless vital signs monitoring

July 8, 2026

Latest business and industry news

Agilent completes $240m Proscia acquisition to expand AI-enabled pathology
Thomson Reuters revenue rises 10%, so why did TRI fall 7% on its AI strategy?
Thames Water names nine teams for £4bn projects framework as debt talks continue
Japan launches National Disaster Management Agency as megaquake threat looms
Boeing wins $119.7m P-8A upgrade order as defence margins remain under pressure

TAGS

AstraZeneca clinical trials Eli Lilly and Company European Medicines Agency FDA FDA approval immunotherapy Inc. Johnson & Johnson medical devices non-small cell lung cancer oncology precision oncology U.S. Food and Drug Administration United States Food and Drug Administration

About PharmaDeviceNews
Disclaimer
Editorial Policy
Privacy Policy
Contact Us

© 2026 PharmaDeviceNews.com. All rights reserved.